Clinical Trial Update: Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab with or without defactinib after chemotherapy as neoadjuvant and adjuvant therapy for resectable pancreatic ductal adenoc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Defactinib (defactinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Lei Zheng | Conditions: Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2026-02-04